PetVivo Holdings, Inc. Stock

Equities

PETV

US7168174081

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 03:40:57 2024-04-23 pm EDT 5-day change 1st Jan Change
0.84 USD +5.00% Intraday chart for PetVivo Holdings, Inc. +16.67% -20.75%
Sales 2024 * 2.66M Sales 2025 * 8.9M Capitalization 14.09M
Net income 2024 * -12M Net income 2025 * -9M EV / Sales 2024 * 5.3 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.58 x
P/E ratio 2024 *
-0.82 x
P/E ratio 2025 *
-1.27 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.57%
More Fundamentals * Assessed data
Dynamic Chart
PetVivo Holdings, Inc.(OTCPK:PETV) dropped from S&P TMI Index CI
PetVivo Holdings, Inc. announced that it has received $0.3 million in funding from A.L. Sarroff Management, LLC CI
PetVivo Holdings, Inc.(OTCPK:PETV) dropped from NASDAQ Composite Index CI
PetVivo, ThinkEquity Terminate At-The-Market Offering Deal MT
PetVivo Names Garry Lowenthal its New Chief Financial Officer MT
Petvivo Holdings, Inc. Appoints Garry Lowenthal as Its New Chief Financial Officer CI
Transcript : PetVivo Holdings, Inc., Q3 2024 Earnings Call, Feb 12, 2024
PetVivo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Earnings Flash (PETV) PETVIVO HOLDINGS Posts Q3 Revenue $595,891 MT
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-Articular Injections of Spryng? with Osteocushion? Technology CI
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-Articular Injections of Spryng with OsteoCushion Technology CI
Robert J. Folkes Resigns as Chief Financial Officer of PetVivo Holdings, Inc., Effective from February 2, 2024 CI
Petvivo Receives Notice of Allowance from United States Patent and Trademark Office for Key Patent Application CI
PetVivo Holdings, Inc. Approves Election of Diane Levitan as Member of the Board CI
Transcript : PetVivo Holdings, Inc., Q2 2024 Earnings Call, Nov 14, 2023
More news
1 day+5.00%
1 week+16.67%
Current month-21.50%
1 month-20.42%
3 months-28.21%
6 months-44.74%
Current year-20.75%
More quotes
1 week
0.60
Extreme 0.6
0.84
1 month
0.33
Extreme 0.33
1.25
Current year
0.33
Extreme 0.33
1.50
1 year
0.33
Extreme 0.33
2.90
3 years
0.33
Extreme 0.33
13.99
5 years
0.33
Extreme 0.33
17.00
10 years
0.22
Extreme 0.2222
177.78
More quotes
Managers TitleAgeSince
Founder 58 09-03-30
Founder 61 09-03-30
Director of Finance/CFO 64 Mar. 07
Members of the board TitleAgeSince
Director/Board Member 65 22-07-26
Founder 61 09-03-30
Director/Board Member 63 23-04-13
More insiders
Date Price Change Volume
24-04-22 0.8 +8.84% 35,033
24-04-19 0.735 +2.08% 39,036
24-04-18 0.72 0.00% 17,747
24-04-17 0.72 +4.35% 27,539
24-04-16 0.69 +12.20% 79,932

Delayed Quote OTC Markets, April 23, 2024 at 03:40 pm EDT

More quotes
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Company’s lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8 USD
Average target price
5 USD
Spread / Average Target
+525.00%
Consensus